Extensive CArdioVAscular Characterization and Follow-up of Patients Receiving Immune Checkpoint Inhibitors
- Conditions
- Cardiac Abnormalities, VariableImmune-related Adverse EventDiastolic DysfunctionCancerAtherosclerosisCardiotoxicityImmune Checkpoint Inhibitor-Related Myocarditis
- Interventions
- Procedure: Cardiology consultationDiagnostic Test: Chest Computed Tomography (CT) without contrastProcedure: Non-invasive endothelial function testsProcedure: ElectrocardiogramDiagnostic Test: Extra serum sample (7.5 mL)
- Registration Number
- NCT05699915
- Lead Sponsor
- Algemeen Ziekenhuis Maria Middelares
- Brief Summary
The goal of this prospective, multicentre study is to investigate short- and long-term cardiovascular effects in cancer patients treated with immune checkpoint inhibitors (ICIs).
The main question\[s\] it aims to answer are:
* To investigate troponin and NT-proBNP values in patients receiving ICIs and their association with ICI-induced CV abnormalities and MACEs.
* Study the calcium score, systolic, and diastolic (dys)function.
* Evaluate associations between patient/disease characteristics / transthoracic echocardiography parameters / electrocardiography parameters and troponin / NT-proBNP levels.
Participants will be closely monitored by performing the following additional visits and testing:
* Chest CT scan prior to treatment start, after 12 and 24 months.
* Consultation with a cardiologist at baseline, 3, 6, 12 and 24 months, who will perform an electrocardiogram and echocardiogram.
* One additional blood sample prior to treatment start, after 3, 6, 12 and 24 months. An extra blood sample could be taken in case of sudden heart problems.
* Non-invasive endothelial function tests prior to treatment start, after 12 and 24 months.
- Detailed Description
The increasing use of immune checkpoint inhibitors (ICIs) in the treatment of both advanced and early stages of various malignancies has resulted in a substantial increase in the incidence of cardiovascular immune related adverse events (irAEs). The current guidelines are based on anecdotal evidence and expert opinions due to the lack of solid data and prospective studies. Therefore, cardiac monitoring, in patients receiving ICIs, is often not implemented by oncologists as many questions remain unanswered. Hence, the urgent need to investigate the possible short and long term cardiovascular effects of ICIs.
The investigators developed a multicentre, prospective study in which patients with a solid tumour eligible for ICI treatment will be enrolled. The study exists of routine investigations of blood parameters (troponin and (N-terminal) brain-type natriuretic peptide levels in particular) and a thorough cardiovascular follow-up on fixed time points during a period of two years. The cardiovascular follow-up consists of continuous remote patient monitoring, routine cardiology consultations including electrocardiograms, transthoracic echocardiograms, CT-scans for calcium scoring and non-invasive endothelial function tests. Associations between these blood parameters and short and long term cardiovascular irAEs will be statistically analysed.
This project will allow for a better estimate of the incidence of both short and long-term cardiovascular irAEs in a 'real world' patient population receiving ICIs. If the investigators are able to accurately predict and detect short- and long-term cardiovascular irAEs in an early (and subclinical) stage by correct implementation and interpretation of existing cardiac markers, they could be managed early on in a more effective manner.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 105
- Have a solid tumour and will receive one of the following therapies based on current evidence based clinical guidelines: anti-programmed cell death protein-1 (PD-1), anti-programmed cell death ligand-1 (PD-L1) and/or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) therapy
- Be literate in Dutch or English
- Prior treatment with immunotherapy (immune checkpoint inhibitors, T-cell transfer therapy, cancer treatment vaccines or immune system modulators).
- Patients who will receive ICIs in combination with an additional systemic anti-cancer regimen (chemotherapy, tyrosine kinase inhibitors,...).
- Having a known history of human immunodeficiency virus (HIV) infection.
- Having a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (defined as detectable RNA via qualitative nucleic acid testing) infection.
- Having a diagnosis of immunodeficiency or is receiving chronic/active systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Cancer patients with a solid tumour eligible for treatment with immune checkpoint inhibitors Cardiology consultation Patients are treated as standard of care Cancer patients with a solid tumour eligible for treatment with immune checkpoint inhibitors Chest Computed Tomography (CT) without contrast Patients are treated as standard of care Cancer patients with a solid tumour eligible for treatment with immune checkpoint inhibitors Extra serum sample (7.5 mL) Patients are treated as standard of care Cancer patients with a solid tumour eligible for treatment with immune checkpoint inhibitors Non-invasive endothelial function tests Patients are treated as standard of care Cancer patients with a solid tumour eligible for treatment with immune checkpoint inhibitors Electrocardiogram Patients are treated as standard of care
- Primary Outcome Measures
Name Time Method The incidence of an elevated hs-TnT above the ULN if the baseline value was normal; or 1.5 ≥ times baseline if the baseline value was above the ULN within the first three months of treatment. The maximum measured value will be taken into account. Preliminary analysis once 50 patients have reached their 3-month cardiac follow-up visit and 3 months after last patient is included. For the primary endpoint, the cumulative incidence of troponin elevation will be calculated with death as a competing risk. Cumulative incidences and corresponding 95% confidence intervals will be reported and a cumulative incidence plot will be used to visualize the results.
- Secondary Outcome Measures
Name Time Method The incidence of hs-TnT/NT-proBNP elevations at baseline, 3, 6, 12, and 24 months. Preliminary analysis once 50 patients have reached their 3-month cardiac follow-up visit and through study completion, an average of 1 year Cumulative incidences and 95% confidence intervals, considering death as a competing event.
Evolution of transthoracic 3D echocardiography parameters (dimensions, diastolic function, valvular abnormalities, LVEF, strain analysis) at baseline, 3, 6, 12, and 24 months. reliminary analysis once 50 patients have reached their 3-month cardiac follow-up visit and through study completion, an average of 1 year Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual.
Association between the evolution of troponin/NT-proBNP and transthoracic echocardiography parameters at baseline, 3, 6, 12, and 24 months. reliminary analysis once 50 patients have reached their 3-month cardiac follow-up visit and through study completion, an average of 1 year Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual.
Overall survival. reliminary analysis once 50 patients have reached their 3-month cardiac follow-up visit and through study completion, an average of 1 year Cumulative incidences and 95% confidence intervals
The difference in the evolution of transthoracic echocardiography parameters (dimensions, diastolic function, valvular abnormalities, LVEF, strain analysis) between combination therapy and monotherapy over a period of two years. Through study completion, an average of 1 year Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
The incidence of hs-TnT/NT-proBNP elevations at 6, 12, and 24 months. Through study completion, an average of 1 year Cumulative incidences and 95% confidence intervals, considering death as a competing event.
Association between the evolution of troponin/NT-proBNP and MACEs over a period of two years. Nonfatal stroke, nonfatal myocardial infarction, hospital admission for heart failure, cardiac revascularization and CV death will be combined to report MACEs. Through study completion, an average of 1 year Joint model combining a linear mixed model for troponin and a sub-distributional proportional hazards model for the time-to-event taking into account death as a competing event for CV abnormality and MACE.
Association between the evolution of troponin and diastolic function (based on the recommendations listed in https://doi.org/10.1016/j.echo.2016.01.011, mitral inflow, tissue doppler imaging parameters). Through study completion, an average of 1 year Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
Calcium score at baseline, 12 months, and 24 months. Through study completion, an average of 1 year Proportions and 95% confidence interval
Agreement between hs-TnT and hs-TnI levels at baseline, 3, 6, 12, and 24 months. reliminary analysis once 50 patients have reached their 3-month cardiac follow-up visit and through study completion, an average of 1 year Bland-Altman curves and intraclass correlation coefficient (ICC) based on a two-way mixed effects model. The ICC and 95% confidence interval will be reported.
Association between patient characteristics (demographics, medical history, current oncological disease, prior cancer history, prior/concomitant medication and other relevant parameters) and troponin. Through study completion, an average of 1 year Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
Association between patient characteristics (demographics, medical history, current oncological disease, prior cancer history, prior/concomitant medication and other relevant parameters) and NT-proBNP. Through study completion, an average of 1 year Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
The proportion of severe immune-related non-CV toxicities (grades 3-5). Through study completion, an average of 1 year Proportions and 95% confidence interval
Association between the evolution of troponin/NT-proBNP and severe immune-related non-CV toxicities (grades 3-5, e.g. pneumonitis, colitis, thyroiditis, etc. according to the CTCAE criteria). Through study completion, an average of 1 year Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
Peripheral vascular function at baseline, 3 months, 6 months, 12 months and 24 months. Through study completion, an average of 1 year Flow mediated dilatation: dilatation % from baseline to maximal post-occlusion diameter.
Peripheral arterial tonometry ratio: based on the response to reactive hyperemia using post and pre-occlusion valuesAssociation between the evolution of troponin and calcium score. Through study completion, an average of 1 year Flow mediated dilatation: dilatation % from baseline to maximal post-occlusion diameter.
Peripheral arterial tonometry ratio: based on the response to reactive hyperemia using post and pre-occlusion valuesAssociation between the evolution of troponin/NT-proBNP and electrocardiography (rhythm, heart axis, PQ, QRS, bundle branch block, QT, RR, pathological Q's, left ventricular hypertrophy and STT segments) parameters at baseline, 3, 6, 12, and 24 months. reliminary analysis once 50 patients have reached their 3-month cardiac follow-up visit and through study completion, an average of 1 year Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual.
Cumulative incidence of cardiovascular (CV) abnormalities at 3, 6, 12, and 24 months based on the CARDIOTOX classification system of Sendón et al., with the inclusion of pericardial effusion and new arrhythmias. Through study completion, an average of 1 year Cumulative incidences and 95% confidence intervals, considering death as a competing event.
Evolution of hs-TnT/NT-proBNP in 24 months compared to baseline. Through study completion, an average of 1 year Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual.
Association between the evolution of troponin/NT-proBNP and CV abnormalities (as classified based on the CARDIOTOX classification for myocardial injury including cardiac biomarkers, symptoms, LVEF, LA area, LVESV, GLS and diastolic function). Through study completion, an average of 1 year Joint model combining a linear mixed model for troponin and a sub-distributional proportional hazards model for the time-to-event taking into account death as a competing event for CV abnormality and MACE.
Cumulative incidence of MACEs at 3, 6, 12, and 24 months. MACEs were defined as the composite outcome of nonfatal stroke, nonfatal myocardial infarction, hospital admission for heart failure (HF) and cardiac revascularization, and CV death. Through study completion, an average of 1 year Cumulative incidences and 95% confidence intervals, considering death as a competing event.
The difference in the evolution of hs-TnT/NT-proBNP between combination therapy and monotherapy over a period of two years. Through study completion, an average of 1 year Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
The difference in the evolution of electrocardiography parameters (rhythm, heart axis, PQ, QRS, bundle branch block, QT, RR, pathological Q's, left ventricular hypertrophy and STT segments) between combination therapy and monotherapy. Through study completion, an average of 1 year Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual. This model will be extended with patient and treatment characteristics and their interaction with time, to evaluate their impact on the evolution of these parameters.
Association between the evolution of troponin/NT-proBNP and overall survival. Through study completion, an average of 1 year Joint model combining a linear mixed model for troponin and a sub-distributional proportional hazards model for the time-to-event taking into account death as a competing event for CV abnormality and MACE.
Evolution of electrocardiography parameters (rhythm, heart axis, PQ interval, QRS duration, bundle branch block, QT interval, RR interval, pathological Q's, left ventricular hypertrophy and STT segments) at baseline, 3, 6, 12, and 24 months. reliminary analysis once 50 patients have reached their 3-month cardiac follow-up visit and through study completion, an average of 1 year Linear mixed effects model with a random intercept per subject to account for the correlation measurements coming from the same individual.
Trial Locations
- Locations (4)
AZ Sint-Vincentius Deinze
🇧🇪Deinze, East-Flanders, Belgium
Algemeen Ziekenhuis Maria Middelares
🇧🇪Ghent, East-Flanders, Belgium
AZ Sint-Elisabeth Zottegem
🇧🇪Zottegem, East-Flanders, Belgium
Antwerp University Hospital
🇧🇪Antwerp, Belgium